Aurobindo Receives FDA Approval for Allopurinol Tablets USP, 100 mg and 300 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Allopurinol Tablets USP, 100 mg and 300 mg. Aurobindo Pharma’s Allopurinol Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Zyloprim Tablets manufactured by Casper Pharma LLC. Allopurinol Tablets […]

Aurobindo Receives FDA Approval for Allopurinol Tablets USP, 100 mg and 300 mg Read More »

Aurobindo Receives FDA Approval for Rivaroxaban Tablets USP, 2.5 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Rivaroxaban Tablets USP, 2.5 mg. Aurobindo Pharma’s Rivaroxaban Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Xarelto Tablets manufactured by Janssen Pharmaceuticals, Inc. (Janssen). Rivaroxaban Tablets are indicated:

Aurobindo Receives FDA Approval for Rivaroxaban Tablets USP, 2.5 mg Read More »

Aurobindo Receives FDA Approval for Dapsone Gel, 5%

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Dapsone Gel, 5%. Aurobindo Pharma’s Dapsone Gel, are an AB-rated generic equivalent to the reference listed drug (RLD), Aczone Gel manufactured by AbbVie Inc. Dapsone Gel are indicated for the: Topical treatment

Aurobindo Receives FDA Approval for Dapsone Gel, 5% Read More »

Aurobindo Receives FDA Approval for Pantoprazole Sodium for Delayed-Release Oral Suspension, 40 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Pantoprazole Sodium for Delayed-Release Oral Suspension, 40 mg. Aurobindo Pharma’s Pantoprazole Sodium for Delayed-Release Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), Protonix for Delayed-Release Oral Suspension

Aurobindo Receives FDA Approval for Pantoprazole Sodium for Delayed-Release Oral Suspension, 40 mg Read More »

Aurobindo Receives FDA Approval for Nystatin Cream USP, 100,000 units per gram

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Nystatin Cream USP, 100,000 units per gram. Aurobindo Pharma’s Nystatin Cream, are an AB-rated generic equivalent to the reference listed drug (RLD), Nystatin Cream manufactured by Taro Pharmaceuticals Inc., Nystatin Cream are

Aurobindo Receives FDA Approval for Nystatin Cream USP, 100,000 units per gram Read More »

Aurobindo Receives FDA Approval for Tretinoin Gel USP, 0.025%

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Tretinoin Gel USP, 0.025%. Aurobindo Pharma’s Tretinoin Gel, are an AB-rated generic equivalent to the reference listed drug (RLD), Retin-A® Gel manufactured by Bausch Health US, LLC. Tretinoin Gel are indicated for:

Aurobindo Receives FDA Approval for Tretinoin Gel USP, 0.025% Read More »

Aurobindo Pharma Breaks Ground On East Windsor Campus

Aurobindo is building a new 170,000-square-foot building in East Windsor. Aurobindo is building a new 170,000-square-foot building on the Aurobindo campus, a state-of-the art pharmaceutical manufacturing facility on Windsor Center Drive. The new building will join the existing 606,620 square foot Aurobindo building constructed in 2016 and the previously acquired 43,000 square foot Patscenter building

Aurobindo Pharma Breaks Ground On East Windsor Campus Read More »

Aurobindo Receives FDA Approval for Tretinoin Gel USP, 0.01%

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Tretinoin Gel USP, 0.01%. Aurobindo Pharma’s Tretinoin Gel, are an AB-rated generic equivalent to the reference listed drug (RLD), Retin-A® Gel manufactured by Bausch Health US, LLC. Tretinoin Gel are indicated for:

Aurobindo Receives FDA Approval for Tretinoin Gel USP, 0.01% Read More »

Aurobindo Receives FDA Approval for Glycopyrrolate Oral Solution, 1 mg/5 mL

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Glycopyrrolate Oral Solution, 1 mg/5 mL. Aurobindo Pharma’s Glycopyrrolate Oral Solution, are an AB-rated generic equivalent to the reference listed drug (RLD), Cuvposa® Oral Solution manufactured by Merz Pharmaceuticals, LLC. Glycopyrrolate Oral

Aurobindo Receives FDA Approval for Glycopyrrolate Oral Solution, 1 mg/5 mL Read More »

Aurobindo Receives FDA Approval for Deutetrabenazine Tablets, 6 mg, 9 mg, and 12 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Deutetrabenazine Tablets, 6 mg, 9 mg, and 12 mg. Aurobindo Pharma’s Deutetrabenazine Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Austedo® Tablets manufactured by Teva Branded Pharmaceuticals Products

Aurobindo Receives FDA Approval for Deutetrabenazine Tablets, 6 mg, 9 mg, and 12 mg Read More »

Aurobindo Receives FDA Approval for Clozapine Orally Disintegrating Tablets, 12.5 mg, 25 mg, 100 mg, 150 mg, and 200 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Clozapine Orally Disintegrating Tablets, 12.5 mg, 25 mg, 100 mg, 150 mg, and 200 mg. Aurobindo Pharma’s Clozapine Orally Disintegrating Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD),

Aurobindo Receives FDA Approval for Clozapine Orally Disintegrating Tablets, 12.5 mg, 25 mg, 100 mg, 150 mg, and 200 mg Read More »

Aurobindo Receives FDA Approval for Cimetidine Tablets USP, 200 mg, 300 mg, 400 mg, and 800 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Cimetidine Tablets USP, 200 mg, 300 mg, 400 mg, and 800 mg. Aurobindo Pharma’s Cimetidine Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Tagamet® Tablets manufactured by Glaxosmithkline

Aurobindo Receives FDA Approval for Cimetidine Tablets USP, 200 mg, 300 mg, 400 mg, and 800 mg Read More »